drugset / Trial / NCT01347671

Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy

NCT01347671

Phase 2 Completed 189 enrolled Tris Pharma, Inc. Forest Laboratories · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to investigate the efficacy and safety of GRT6005 in patients with painful diabetic neuropathy.

Timeline

Start
2011-05
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cebranopadol Small molecule 25 ug
Comparator Cebranopadol Small molecule 75 ug
Comparator Cebranopadol Small molecule 200 ug